Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pleiotropic Effects of Dapagliflozin in Acute Coronary Syndromes
NCT06286878Phase 3Recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Dec 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myocardial infarction (AMI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Platelet aggregation using ADP at 48 hours. Started Dec 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT06286878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286878.